MILWAUKEE, Oct. 31, 2020 /PRNewswire/ -- Promentis
Pharmaceuticals, Inc., a privately held biopharmaceutical company
developing innovative therapies for neuropsychiatric disorders,
announced that Dr. Chad E. Beyer,
Senior Vice President of R&D, will present psychometric results
from Promentis' Phase 2 clinical study conducted in
trichotillomania patients.
Dr. Beyer's virtual presentation will occur on Saturday, October 31 and will highlight the
continued safety and psychometric activity of the company's lead
clinical molecule, SXC-2023, a drug designed to restore cognitive
control over repetitive, maladaptive behaviors.
About Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. is a privately held
biopharmaceutical company developing innovative therapies for
impulse control and other neuropsychiatric disorders. Promentis'
drug development efforts are focused on a unique approach to
addressing glutamatergic imbalance. The Company's first indication
is trichotillomania, a highly prevalent disorder for which there is
no approved therapy and for which there are no other known
treatments in development.
Contact:
Tiberend Strategic Advisors, Inc.
212-375-2665
jrando@tiberend.com
View original
content:http://www.prnewswire.com/news-releases/promentis-pharmaceuticals-to-present-at-the-11th-anniversary-cns-summit-301164266.html
SOURCE Promentis Pharmaceuticals, Inc.